John Brekken

Broad Antitumor and Antiangiogenic Activities of AG3340, a Potent and Selective MMP Inhibitor Undergoing Advanced Oncology Clinical Trials

David R. Shalinsky, John Brekken, Helen Y. Zou et al. · Annals of the New York Academy of Sciences · 1999 · 238 citations

Medicine, Pharmacokinetics, Pharmacology +10

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90

Karen Lundgren, Hong Zhang, John Brekken et al. · Molecular Cancer Therapeutics · 2009 · 170 citations · Full text

Medicine, Oncology, Pharmacology +12

Rationally Designed High-Affinity 2-Amino-6-halopurine Heat Shock Protein 90 Inhibitors That Exhibit Potent Antitumor Activity

Srinivas Rao Kasibhatla, Kevin Hong, Marco A. Biamonte et al. · Journal of Medicinal Chemistry · 2007 · 125 citations · Full text

Medicine, Oncology, Pharmacology +14

Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies.

David R. Shalinsky, John Brekken, Helen Y. Zou et al. · PubMed · 1999 · 86 citations

Medicine, Oncology, Pharmacology +17

Identification of new biomarkers for clinical trials of Hsp90 inhibitors

Hong Zhang, Daun Chung, Yong‐Ching Yang et al. · Molecular Cancer Therapeutics · 2006 · 61 citations

Medicine, Oncology, Pharmacology +14